Pay for performance for specialised care in England: Strengths and weaknesses.


Journal

Health policy (Amsterdam, Netherlands)
ISSN: 1872-6054
Titre abrégé: Health Policy
Pays: Ireland
ID NLM: 8409431

Informations de publication

Date de publication:
11 2019
Historique:
received: 27 12 2018
revised: 29 05 2019
accepted: 09 07 2019
pubmed: 14 8 2019
medline: 17 9 2020
entrez: 14 8 2019
Statut: ppublish

Résumé

Pay-for-Performance (P4P) schemes have become increasingly common internationally, yet evidence of their effectiveness remains ambiguous. P4P has been widely used in England for over a decade both in primary and secondary care. A prominent P4P programme in secondary care is the Commissioning for Quality and Innovation (CQUIN) framework. The most recent addition to this framework is Prescribed Specialised Services (PSS) CQUIN, introduced into the NHS in England in 2013. This study offers a review and critique of the PSS CQUIN scheme for specialised care. A key feature of PSS CQUIN is that whilst it is centrally developed, performance targets are agreed locally. This means that there is variation across providers in the schemes selected from the national menu, the achievement level needed to earn payment, and the proportion of the overall payment attached to each scheme. Specific schemes vary in terms of what is incentivised - structure, process and/or outcome - and how they are incentivised. Centralised versus decentralised decision making, the nature of the performance measures, the tiered payment structure and the dynamic nature of the schemes have created a sophisticated but complex P4P programme which requires evaluation to understand the effect of such incentives on specialised care.

Identifiants

pubmed: 31405615
pii: S0168-8510(19)30167-8
doi: 10.1016/j.healthpol.2019.07.007
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Pagination

1036-1041

Informations de copyright

Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.

Auteurs

Yan Feng (Y)

Centre for Primary Care and Public Health, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, E1 2AB, London, UK.

Søren Rud Kristensen (SR)

Centre for Health Policy, Institute of Global Health Innovation, Imperial College London, SW7 2A, London, UK.

Paula Lorgelly (P)

Office of Health Economics, SW1E 6QT, London, UK; Faculty of Life Sciences and Medicine, King's College London, WC2R 2LS, London, UK.

Rachel Meacock (R)

School of Health Sciences, University of Manchester, M13 9PL, Manchester, UK.

Marina Rodes Sanchez (MR)

Office of Health Economics, SW1E 6QT, London, UK.

Luigi Siciliani (L)

Department of Economics and Related Studies, University of York, YO10 5DD, York, UK. Electronic address: luigi.siciliani@york.ac.uk.

Matt Sutton (M)

School of Health Sciences, University of Manchester, M13 9PL, Manchester, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH